Becton, Dickinson and Company (BDX) Updates FY18 Earnings Guidance
Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of 10.55-10.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.41.
Shares of Becton, Dickinson and Company (NYSE BDX) opened at $224.41 on Friday. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The company has a market cap of $50.98 billion, a price-to-earnings ratio of 23.61, a P/E/G ratio of 1.77 and a beta of 1.04.
Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter last year, the business posted $2.12 EPS. Becton, Dickinson and’s quarterly revenue was down 2.0% compared to the same quarter last year. research analysts forecast that Becton, Dickinson and Company will post 10.65 earnings per share for the current year.
A number of research analysts have commented on the company. Barclays PLC reaffirmed an equal weight rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Royal Bank Of Canada reaffirmed a sector perform rating and set a $230.00 target price (up previously from $210.00) on shares of Becton, Dickinson and in a report on Friday. Morgan Stanley increased their target price on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an equal weight rating in a report on Friday. Stifel Nicolaus reaffirmed a buy rating and set a $245.00 target price on shares of Becton, Dickinson and in a report on Friday. Finally, BidaskClub downgraded Becton, Dickinson and from a strong-buy rating to a buy rating in a report on Monday, July 31st. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $211.94.
In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,044 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the sale, the insider now owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last three months, insiders sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Updates FY18 Earnings Guidance” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-updates-fy18-earnings-guidance/1678150.html.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.